Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient

Timothy E. Bunchman, Rulan S. Parekh, David B. Kershaw, William E. Smoyer, Joseph T. Flynn, Rudolph P. Valentini, Aileen B. Sedman

Research output: Contribution to journalArticle

Abstract

The use of pooled immunoglobulin (IgG) has been shown to decrease panel reactive antibodies (PRA) in highly sensitized patients awaiting transplantation. IgG infusions have also been found effective for CMV prophylaxis. Analysis of 52 non-highly sensitized children (ages 1-18) who received kidney transplants from May 1991 through January 1995 was undertaken to determine if the immunoglobulin administered for CMV prophylaxis effected allograft survival. Comparison of the 'Sando Pos' group (those who received Sandoglobulin for CMV prophylaxis) to the 'Sando Neg' group demonstrates a significantly improved allograft survival at 1, 2, and 3 yr post-transplantation. Despite the Sando Pos group being younger [7.3 ± 1.3 yr vs. 10.7 ± 0.9 yr; (mean ± SEM) p <0.05] allograft survival was 95%, 95% and 88% in the Sando Pos group vs. 88%, 79% and 79% in the Sando Neg group at 1, 2 and 3 yr, respectively (p <0.01 at all three time points). It is concluded that the potential mechanism of the immunosuppressive benefit of Sandoglobulin is speculative but presumed to be upon inhibition of anti-HLA class I antibodies. We conclude that Sandoglobulin may not be useful for CMV prophylaxis but also as an adjunct to routine immunosuppression.

Original languageEnglish (US)
Pages (from-to)604-607
Number of pages4
JournalClinical Transplantation
Volume11
Issue number6
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Allografts
Pediatrics
Kidney
Immunoglobulins
Immunoglobulin G
Transplantation
Immunoglobulin Isotypes
Immunosuppressive Agents
Immunosuppression
Transplant Recipients
Ataxia Neuropathy Spectrum
Transplants
Antibodies

Keywords

  • Panel reactive antibodies
  • Pooled immunoglobulin
  • T-cell induction

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Bunchman, T. E., Parekh, R. S., Kershaw, D. B., Smoyer, W. E., Flynn, J. T., Valentini, R. P., & Sedman, A. B. (1997). Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clinical Transplantation, 11(6), 604-607.

Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. / Bunchman, Timothy E.; Parekh, Rulan S.; Kershaw, David B.; Smoyer, William E.; Flynn, Joseph T.; Valentini, Rudolph P.; Sedman, Aileen B.

In: Clinical Transplantation, Vol. 11, No. 6, 12.1997, p. 604-607.

Research output: Contribution to journalArticle

Bunchman, TE, Parekh, RS, Kershaw, DB, Smoyer, WE, Flynn, JT, Valentini, RP & Sedman, AB 1997, 'Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient', Clinical Transplantation, vol. 11, no. 6, pp. 604-607.
Bunchman TE, Parekh RS, Kershaw DB, Smoyer WE, Flynn JT, Valentini RP et al. Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clinical Transplantation. 1997 Dec;11(6):604-607.
Bunchman, Timothy E. ; Parekh, Rulan S. ; Kershaw, David B. ; Smoyer, William E. ; Flynn, Joseph T. ; Valentini, Rudolph P. ; Sedman, Aileen B. / Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. In: Clinical Transplantation. 1997 ; Vol. 11, No. 6. pp. 604-607.
@article{ea5f46ce947b47f796398002ee7fa0d5,
title = "Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient",
abstract = "The use of pooled immunoglobulin (IgG) has been shown to decrease panel reactive antibodies (PRA) in highly sensitized patients awaiting transplantation. IgG infusions have also been found effective for CMV prophylaxis. Analysis of 52 non-highly sensitized children (ages 1-18) who received kidney transplants from May 1991 through January 1995 was undertaken to determine if the immunoglobulin administered for CMV prophylaxis effected allograft survival. Comparison of the 'Sando Pos' group (those who received Sandoglobulin for CMV prophylaxis) to the 'Sando Neg' group demonstrates a significantly improved allograft survival at 1, 2, and 3 yr post-transplantation. Despite the Sando Pos group being younger [7.3 ± 1.3 yr vs. 10.7 ± 0.9 yr; (mean ± SEM) p <0.05] allograft survival was 95{\%}, 95{\%} and 88{\%} in the Sando Pos group vs. 88{\%}, 79{\%} and 79{\%} in the Sando Neg group at 1, 2 and 3 yr, respectively (p <0.01 at all three time points). It is concluded that the potential mechanism of the immunosuppressive benefit of Sandoglobulin is speculative but presumed to be upon inhibition of anti-HLA class I antibodies. We conclude that Sandoglobulin may not be useful for CMV prophylaxis but also as an adjunct to routine immunosuppression.",
keywords = "Panel reactive antibodies, Pooled immunoglobulin, T-cell induction",
author = "Bunchman, {Timothy E.} and Parekh, {Rulan S.} and Kershaw, {David B.} and Smoyer, {William E.} and Flynn, {Joseph T.} and Valentini, {Rudolph P.} and Sedman, {Aileen B.}",
year = "1997",
month = "12",
language = "English (US)",
volume = "11",
pages = "604--607",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient

AU - Bunchman, Timothy E.

AU - Parekh, Rulan S.

AU - Kershaw, David B.

AU - Smoyer, William E.

AU - Flynn, Joseph T.

AU - Valentini, Rudolph P.

AU - Sedman, Aileen B.

PY - 1997/12

Y1 - 1997/12

N2 - The use of pooled immunoglobulin (IgG) has been shown to decrease panel reactive antibodies (PRA) in highly sensitized patients awaiting transplantation. IgG infusions have also been found effective for CMV prophylaxis. Analysis of 52 non-highly sensitized children (ages 1-18) who received kidney transplants from May 1991 through January 1995 was undertaken to determine if the immunoglobulin administered for CMV prophylaxis effected allograft survival. Comparison of the 'Sando Pos' group (those who received Sandoglobulin for CMV prophylaxis) to the 'Sando Neg' group demonstrates a significantly improved allograft survival at 1, 2, and 3 yr post-transplantation. Despite the Sando Pos group being younger [7.3 ± 1.3 yr vs. 10.7 ± 0.9 yr; (mean ± SEM) p <0.05] allograft survival was 95%, 95% and 88% in the Sando Pos group vs. 88%, 79% and 79% in the Sando Neg group at 1, 2 and 3 yr, respectively (p <0.01 at all three time points). It is concluded that the potential mechanism of the immunosuppressive benefit of Sandoglobulin is speculative but presumed to be upon inhibition of anti-HLA class I antibodies. We conclude that Sandoglobulin may not be useful for CMV prophylaxis but also as an adjunct to routine immunosuppression.

AB - The use of pooled immunoglobulin (IgG) has been shown to decrease panel reactive antibodies (PRA) in highly sensitized patients awaiting transplantation. IgG infusions have also been found effective for CMV prophylaxis. Analysis of 52 non-highly sensitized children (ages 1-18) who received kidney transplants from May 1991 through January 1995 was undertaken to determine if the immunoglobulin administered for CMV prophylaxis effected allograft survival. Comparison of the 'Sando Pos' group (those who received Sandoglobulin for CMV prophylaxis) to the 'Sando Neg' group demonstrates a significantly improved allograft survival at 1, 2, and 3 yr post-transplantation. Despite the Sando Pos group being younger [7.3 ± 1.3 yr vs. 10.7 ± 0.9 yr; (mean ± SEM) p <0.05] allograft survival was 95%, 95% and 88% in the Sando Pos group vs. 88%, 79% and 79% in the Sando Neg group at 1, 2 and 3 yr, respectively (p <0.01 at all three time points). It is concluded that the potential mechanism of the immunosuppressive benefit of Sandoglobulin is speculative but presumed to be upon inhibition of anti-HLA class I antibodies. We conclude that Sandoglobulin may not be useful for CMV prophylaxis but also as an adjunct to routine immunosuppression.

KW - Panel reactive antibodies

KW - Pooled immunoglobulin

KW - T-cell induction

UR - http://www.scopus.com/inward/record.url?scp=0030696685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030696685&partnerID=8YFLogxK

M3 - Article

C2 - 9408693

AN - SCOPUS:0030696685

VL - 11

SP - 604

EP - 607

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -